Qingzaobujin Decoction Clinical Study Of Sj(?)gren's Syndrome

Objective:By observing the clinical effects of qingzaobujin decoction to pSS patients in active stage, to study the mechanism of this prescription restrained destruction of gland inflammation and improved glandular secretion function, to provide basis for future clinical application. Methods:By applying random methods, based on maintaining the way of life of 30 standard cases, administered qingzaobujin decoction orally, one dose per day.3 months for a treatment period, counted effects after a treatment period. Observed those efficacy determination, target detection, TCM and symptom score, and for the first time, applied SSDAI which established by the European Rheumatism Union Working Group, headed by professor Vitali, to strengthen the scientificalness of clinical research, thereby to validate its function that suppressing damage of gland inflammation and improving glandular secretion furtherly. Results:In clinical indicators, the total effective rate was 93.33%, effective rate of syndromes in Chinese medicine was 96.67%, efficiency change between two groups showed significant difference (P<0.01); there were significant differences between before and after treatment (P<0.01); SSDAI score before and after treatment had significant difference (P<0.01), and TCM symptom score before and after treatment also showed significant difference (P<0.01); symptoms such as their dryness of mouth, pharynx and eyes, joint pain, constipation, dry skin and manifestation of tongue and pulse had significant difference (P<0.05); as the relevant immunological indicators, anti-SSA, anti-SSB, ANA, RF, Schimer experiment, Salivary flow rate test, Parotid sialography, the positive rate of them had turned into negative in varying degrees after treatment, obviously the reduction of anti-SSA, Schirmer positive rate (P<0.05), while change of ANA and Parotid sialography were not siginificant, after treatment, positive rate of those immunological parameters between groups had no significant difference. Besides, after administered this prescription, ESR, CRP, IgG, IgM and IgA were improved effectively, had significant difference (P<0.01); comparison of plasma viscosity before and after treatment were significant different (P<0.05); as T cell subset, changes of CD4+ and CD8+ were obvious (P<0.01), and also was change of CD4+/CD8+(P<0.05).Conclusions:Applying QZBJ therapeutic method to pSS patients in active stage, it can improve the patients'clinical symptoms, signs and some immune indices, and the key of pSS's pathogenesis lies in "Bleeding knotted dry drugs each other, the distribution of body fluid encountered the obstacles"...